Search results for "Highlights"
Diabetes and prior CVD may no longer carry equivalent cardiovascular risk
In a population-based Canadian study, the magnitude of the association between diabetes and risk of cardiovascular events decreased while that between cardiovascular disease (CVD) and such events remained stable.
https://diabetes.acponline.org/archives/2022/11/11/3.htm
11 Nov 2022
Newer oral diabetes meds could provide significant benefits in type 1 diabetes
A retrospective chart review found that glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors were associated with benefits including weight loss and reduced use of insulin in patients with type 1 diabetes.
https://diabetes.acponline.org/archives/2022/11/11/1.htm
11 Nov 2022
Spotlight on diabetes drug class comparisons
A large trial compared insulin, a sulfonylurea, a glucagon-like peptide-1 (GLP-1) receptor agonist, and a dipeptidyl peptidase-4 inhibitor as second-line therapy, while a modeling study considered GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors as first-line agents.
https://diabetes.acponline.org/archives/2022/10/14/5.htm
14 Oct 2022
Time-restricted eating may help improve metabolic status
People who time-restricted their eating had decreased body weight and fat mass and improved lipid values but did not show improvements in waist circumference, HbA1c level, or blood pressure, a systematic review and meta-analysis found.
https://diabetes.acponline.org/archives/2022/10/14/2.htm
14 Oct 2022
ADA, KDIGO offer consensus statements on managing diabetes and chronic kidney disease
The American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) provided specific advice on use of metformin, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists in patients with diabetes and chronic kidney disease.
https://diabetes.acponline.org/archives/2022/10/14/1.htm
14 Oct 2022
Gestational diabetes associated with risks later in life, but lifestyle makes a difference, studies find
A review found increased risks of cardiovascular and cerebrovascular disease in women who had gestational diabetes, while another study showed that five markers of a healthy lifestyle were associated with a significant reduction in risk of developing type 2 diabetes after gestational diabetes.
https://diabetes.acponline.org/archives/2022/10/14/8.htm
14 Oct 2022
Avoiding hypoglycemia most compelling reason for deintensifying diabetes meds
Researchers presented older adults with type 2 diabetes with three scenarios in which deintensification may be indicated—poor health, limited life expectancy, and high hypoglycemia risk—and found that 8%, 4%, and 75%, respectively, viewed deintensification positively.
https://diabetes.acponline.org/archives/2022/10/14/3.htm
14 Oct 2022
Initiation of glucose-lowering therapies may be associated with reduced physical activity
An analysis of 148 participants from three randomized trials found that starting liraglutide, empagliflozin, or sitagliptin was associated with reduction in physical activity of about 1,000 steps per day or 10 minutes of moderate to vigorous physical activity per day.
https://diabetes.acponline.org/archives/2022/09/16/2.htm
16 Sep 2022
Patients diagnosed by OGTT without elevated HbA1c had similar CV, renal disease risks as those without diabetes
A prospective U.K. study found that patients with diabetes based on an oral glucose tolerance test (OGTT) often did not have a diabetic HbA1c level, and risks of cardiovascular (CV) and kidney disease in these patients were similar to those in the nondiabetic general population.
https://diabetes.acponline.org/archives/2022/09/16/3.htm
16 Sep 2022
Program directs stable diabetes patients from endocrinology back to primary care
One academic health system developed a program to “graduate” patients out of endocrinology visits for their diabetes. Criteria included HbA1c level less than 8.0%, blood pressure less than 140/90 mm Hg, no tobacco use, and use of statins and aspirin if needed.
https://diabetes.acponline.org/archives/2022/09/16/1.htm
16 Sep 2022